ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer

Overview of attention for article published in BMC Cancer, November 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 67 Dimensions

Readers on

mendeley: 49 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 67 publications that cite this research output.

67

The most recent citing publications are shown below. View all 67 publications that cite this research output on Dimensions.

Differential whole-genome doubling based signatures for improvement on clinical outcomes and drug response in patients with breast cancer

Article in Heliyon (March 2024)

Screening of miRNAs as prognostic biomarkers and their associated hub targets across Hepatocellular carcinoma using survival-based bioinformatics approach

Article in Journal of Genetic Engineering and Biotechnology (January 2024)

Dysregulated ANLN reveals immune cell landscape and promotes carcinogenesis by regulating the PI3K/Akt/mTOR pathway in clear cell renal cell carcinoma

Article in Heliyon (December 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.